Antoine Désilets

Professionnel de recherche

Université de Sherbrooke

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Antoine Désilets is a Research Professional at Université de Sherbrooke in Canada. His research primarily focuses on the optimization of TMPRSS2 inhibitors and the development of host-directed protease inhibitors targeting SARS-CoV-2 variants. Recent publications highlight his work on enhancing the pharmacokinetics and efficacy of antiviral compounds against respiratory viruses, including H1N1 and SARS-CoV-2.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (7)

Sára Ferková

Lecturer

Bishop's University

CANADA

View details

Ted Steiner

Professor

The University of British Columbia

CANADA

View details

François Jean

The University of British Columbia

CANADA

View details

Richard Leduc

Professor

Université de Sherbrooke

CANADA

View details

Ivan Robert Nabi

Professor

University of British Columbia Faculty of Medicine

CANADA

View details

Mathias Martins

Assistant Clinical Professor

Pennsylvania State University

UNITED STATES

View details

Pierre-Luc Boudreault

Professor

Université de Sherbrooke

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antoine Désilets

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors

From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals

Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket

Front Cover: Optimization of Ketobenzothiazole‐Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication (ChemMedChem 2/2024)

Optimization of Ketobenzothiazole‐Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication

Functionally impaired isoforms regulate TMPRSS6 proteolytic activity.

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.

Matriptase processing of APLP1 ectodomain alters its homodimerization.

Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature.

Collaborators (7)

Sára Ferková

Ted Steiner

François Jean

Richard Leduc

Ivan Robert Nabi

Mathias Martins

Pierre-Luc Boudreault

Make your next move.

Antoine Désilets

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors

From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals

Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket

Front Cover: Optimization of Ketobenzothiazole‐Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication (ChemMedChem 2/2024)

Optimization of Ketobenzothiazole‐Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication

Functionally impaired isoforms regulate TMPRSS6 proteolytic activity.

A﻿ TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.

Matriptase processing of APLP1 ectodomain alters its homodimerization.

Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature.

Collaborators (7)

Sára Ferková

Ted Steiner

François Jean

Richard Leduc

Ivan Robert Nabi

Mathias Martins

Pierre-Luc Boudreault

Make your next move.

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.